Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VYGR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| VP4896 | Alzheimer's Disease | Phase 3 · NCT00231946 | Completed |
| VY7523 | Alzheimer's Disease (AD) | Phase 1/2 · NCT06874621 | Active not recruiting |
| VY-AADC01 | Idiopathic Parkinson's Disease | Phase 1 · NCT03065192 | Completed |
| VY-AADC02 | Parkinson's Disease | Phase 1 · NCT03562494 | Completed |
| VY1706 High Dose | Alzheimer s Disease | Phase 1 · NCT07764146 | Recruiting |
| VY1706 Mid dose | Alzheimer s Disease | Phase 1 · NCT07764146 | Recruiting |
Also used in these trials (approved or third-party drugs, not VYGR's own candidates): Leuprolide Acetate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VYGR holds $132.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $22.8M/quarter from operations, an estimated runway of 17.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable securities at September 30, 2026, along with amounts expected to be received as reimbursement for development costs under our collaboration and license agreements with Neurocrine and Novartis and interest income…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VYGR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Millennium Management LLC | 5%+ holder (13G) | 4,442,951 | 7.14% | 2026-06-30 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 3,436,000 | 5.52% | 2026-06-30 |
| Alfred Sandrock President and CEO, Director · +402,500 options |
Insider | 472,549 | 0.76% | 2026-04-02 |
| Robin Swartz President · +528,500 options |
Insider | 267,988 | 0.43% | 2026-11-01 |
| Toby Ferguson Chief Medical Officer · +210,000 options |
Insider | 183,914 | 0.30% | 2026-02-06 |
| Todd Alfred Carter Chief Scientific Officer · +308,000 options |
Insider | 178,718 | 0.29% | 2026-11-01 |
| Nathan D. Jorgensen Chief Financial Officer · +150,500 options |
Insider | 151,416 | 0.24% | 2026-02-24 |
| Gregory L. Shiferman SVP and General Counsel · +100,000 options |
Insider | 50,000 | 0.08% | 2026-04-01 |
| Amy Quinlan Principal Accounting Officer |
Insider | 36,749 | 0.06% | 2026-05-08 |
Share count 62,229,182 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VYGR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →